LCD L36021: MolDX: Molecular Diagnostic Tests (MDT) — CGS
Policy LCD-L36021 · Clinical Laboratory
New MolDX policy effective in 2025 may alter billing processes.
Code intelligence
0166U reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code 0166U.
Elevated code risk
Signal breakdown
11 shown · 11 total in platform
Risk: Elevated
0
Critical
0%
7
High
64%
4
Routine
36%
0
Low
0%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
High
LCD L36256: MolDX: Molecular Diagnostic Tests (MDT) — Noridian
Policy LCD-L36256 · Clinical Laboratory
New molecular diagnostics policy may impact billing processes.
LCD L35160: MolDX: Molecular Diagnostic Tests (MDT) — Noridian
Policy LCD-L35160 · Clinical Laboratory
New MolDX guidelines may alter MDT billing processes.
LCD L40187 (Notice Ends 08/09/2026): MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — Palmetto GBA
Policy LCD-L40187 · Clinical Laboratory
New MolDX LCD for MASLD/MASH biomarker tests effective Aug 2026.
LCD L40199 (Notice Ends 08/09/2026): MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — CGS Administrators
Policy LCD-L40199 · Clinical Laboratory
New MolDX LCD for MASLD/MASH biomarker tests effective Aug 2026.
LCD L40197 (Notice Ends 08/09/2026): MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — Noridian
Policy LCD-L40197 · Clinical Laboratory
New LCD governs MASLD/MASH biomarker testing starting Aug 2026.
LCD L40272 (Notice Ends 08/09/2026): MolDX: Biomarker Testing in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — WPS
Policy LCD-L40272 · Clinical Laboratory
New MolDX biomarker LCD for MASLD/MASH liver disease effective Aug 2026.
Proposed LCD DL40197: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — Noridian
Policy LCD-DL40197 · Gastroenterology
Impact on billing for liver disease biomarker testing.
Proposed LCD DL40199: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — CGS
Policy LCD-DL40199 · Gastroenterology
New LCD may affect billing for liver disease biomarker testing.
Proposed LCD DL40187: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — Palmetto GBA
Policy LCD-DL40187 · Gastroenterology
New LCD for biomarker testing in liver disease proposed.
Proposed LCD DL40272: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — WPS
Policy LCD-DL40272 · Gastroenterology
Impact of new LCD on liver disease biomarker testing billing.
Audit documentation
Building an audit file that includes 0166U?
The Tripwire Audit Pack exports 12 months of Clinical Laboratory policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Clinical Laboratory audit pack — $349One-time purchase · not a subscription